Day One Biopharmaceuticals, Inc. (DAWN) Financial Statements (2026 and earlier)

Company Profile

Business Address 1800 SIERRA POINT PARKWAY, SUITE 200
BRISBANE, CA 94005
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments531,720366,347342,269284,309
Cash and cash equivalent124,968230,78485,262284,309
Short-term investments406,752135,563257,007 
Receivables13,876   
Inventory, net of allowances, customer advances and progress billings3,321   
Inventory3,321   
Prepaid expense5,1973,2702,5983,114
Other undisclosed current assets8,2165,6573,0071,945
Total current assets:562,330375,274347,874289,368
Noncurrent Assets
Operating lease, right-of-use asset2,422352699227
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization2,2852082057
Intangible asset, including goodwill, after accumulated amortization15,630   
Intangible asset, excluding goodwill, after accumulated amortization15,630   
Deposits noncurrent assets    71
Other undisclosed noncurrent assets12121446998
Total noncurrent assets:20,4587741,188453
TOTAL ASSETS:582,788376,048349,062289,821
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:68,62526,52416,2108,453
Accounts payable3,2622,5762601,744
Accrued liabilities15,9224,71615,9506,709
Other undisclosed accounts payable and accrued liabilities49,44119,232  
Deferred revenue1,554   
Other undisclosed current liabilities3,2722,984405204
Total current liabilities:73,45129,50816,6158,657
Noncurrent Liabilities
Long-term debt and lease obligation:    16
Liabilities, other than long-term debt6,586 408 
Deferred revenue3,233   
Other liabilities761   
Operating lease, liability2,592 40816
Other undisclosed noncurrent liabilities    (16)
Total noncurrent liabilities:6,586 40816
Total liabilities:80,03729,50817,0238,673
Equity
Equity, attributable to parent, including:502,751346,540332,039281,148
Common stock1097 
Additional paid in capital1,056,738805,107601,771408,629
Accumulated other comprehensive income (loss)849(71) 
Accumulated deficit(554,081)(458,585)(269,668)(127,487)
Other undisclosed equity, attributable to parent    6
Total equity:502,751346,540332,039281,148
TOTAL LIABILITIES AND EQUITY:582,788376,048349,062289,821

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenues131,161   
Gross profit:131,161   
Operating expenses(348,431)(206,064)(146,909)(72,743)
Operating loss:(217,270)(206,064)(146,909)(72,743)
Nonoperating income (expense)128,91817,147(18)(15)
Investment income, nonoperating19,70117,187  
Other nonoperating income (expense)1,217(40)(18)(15)
Loss from continuing operations before income taxes:(88,352)(188,917)(146,927)(72,758)
Income tax expense (benefit)(7,144)   
Loss from continuing operations:(95,496)(188,917)(146,927)(72,758)
Loss before gain (loss) on sale of properties:✕✕✕✕(72,758)
Other undisclosed net income   4,7464
Net loss:(95,496)(188,917)(142,181)(72,754)
Net income attributable to noncontrolling interest    2,109
Net loss available to common stockholders, diluted:(95,496)(188,917)(142,181)(70,645)

Comprehensive Income ($ in thousands)
Annual | Quarterly

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Net loss:(95,496)(188,917)(142,181)(72,754)
Comprehensive loss:(95,496)(188,917)(142,181)(72,754)
Comprehensive income, net of tax, attributable to noncontrolling interest    2,109
Other undisclosed comprehensive income (loss), net of tax, attributable to parent7580(71) 
Comprehensive loss, net of tax, attributable to parent:(95,421)(188,837)(142,252)(70,645)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: